Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Menstrual Cycle Abnormalities, Hormonal Profile, and IGF-1 System in Polycystic Ovary Syndrome Patients: A Randomized, Placebo-Controlled Clinical Trial
Table 1
Baseline characteristics of study subjects in both groups.
Variables
Metformin + placebo ()
Metformin + calcium + vitamin D3 ()
value
Age (years)
23.38 ± 3.54
23.06 ± 3.32
0.788
Weight (kg)
71.39 ± 14.79
64.29 ± 13.02
0.147
Height (cm)
159.29 ± 7.84
158.86 ± 5.59
0.853
BMI (kg/m2)
28.01 ± 4.41
25.48 ± 4.97
0.128
Family history of DM, % (n)
50.0 (8)
27.8 (5)
0.291
Family history of CVD, % (n)
37.5 (6)
61.1 (11)
0.303
Family history of thyroid diseases, % (n)
0.0 (0)
16.7 (3)
0.230
Family history of PCOS, % (n)
25.0 (4)
27.8 (5)
1.000
Smoking, % (n)
50.0 (8)
27.8 (5)
0.291
Drinking alcohol, % (n)
6.3 (1)
5.6 (1)
1.000
Menstrual irregularity, % (n)
81.3 (13)
94.4 (17)
0.323
Hirsutism, % (n)
75.0 (12)
77.8 (14)
1.000
Daily outdoors exposure to the sunlight: >30 minutes, % (n)
62.5 (10)
44.4 (8)
0.327
Sunscreen use, % (n)
62.5 (10)
61.1 (11)
1.000
Hijab, % (n)
75.0 (12)
61.1 (11)
0.477
BMI: body mass index; DM: diabetes mellitus; CVD: cardiovascular diseases; PCOS: polycystic ovary syndrome.
